Our ultra-deep CSF proteome identified most of previously reported AD CSF biomarker candidates (12 out of 13, Supplemental Table S6), however, the majority of them displayed no statistical significance except SMOC1 and TGFB2, which may be due to the small sample size in our pilot study and/or the small changes of these proteins in AD (Fig. 2b). This evidence concerns the gene TGFB2 and Alzheimer disease.